Inclusion Criteria:

          1. Age: 61-80 years

          2. All risk groups (IPI 1-5)

          3. Diagnosis of aggressive CD20+ B-NHL, based on an excisional biopsy of a lymph node or
             on an appropriate sample of a lymph node or of an extranodal involvement. It will be
             possible to treat the following entities in this study as defined by the new WHO
             classification of 200870:

             B-NHL:

               -  Foll. lymphoma grade IIIb

               -  DLBCL, not otherwise specified (NOS)

                    -  common morphologic variants:

                         -  centroblastic

                         -  immunoblastic

                         -  anaplastic

                    -  rare morphologic variants

               -  DLBCL subtypes/entities:

                    -  T-cell/histiocyte-rich large B-cell lymphoma

                    -  primary cutaneous DLBCL, leg type

                    -  EBV-pos. DLBCL of the elderly

               -  DLBCL associated with chronic inflammation

               -  primary mediastinal (thymic) LBCL

               -  intravascular large B-cell-lymphoma

               -  ALK-positive large B-cell-lymphoma

               -  plasmoblastic lymphoma

               -  primary effusion lymphoma

               -  transformed indolent lymphoma secondary or simultaneous high grade
                  B-cell-lymphoma

               -  B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and
                  Burkitt lymphoma

               -  B-cell lymphoma, unclassifiable, with features intermediate between DLCBL and
                  Hodgkin lymphoma

          4. Performance status ECOG 0 - 2 after prephase treatment. The performance status of each
             patient must be assessed before the initiation and after the end of prephase treatment
             which, as experience has shown, can result in a significant improvement of the
             patient's performance status. The pre-treatment performance status which can range
             from ECOG 0 to ECOG 4 must be documented in the Staging CRF (see ISF); the performance
             status after the prephase treatment must be documented in the respective Prephase
             Treatment CRF (PT form: see ISF). A definition of the performance status is provided
             in Appendix 28.10.

          5. Written informed consent of the patient

          6. Contract of participation signed by the study centre and sponsor

        Exclusion Criteria:

          1. Already initiated lymphoma therapy (except for the prephase treatment)

          2. Serious accompanying disorder or impaired organ function (except when due to lymphoma
             involvement), in particular:

               -  heart: angina pectoris CCS >2, cardiac failure e.g. NYHA >2 and/or EF <50% or
                  FS<25% in nuclear medicine examination/echocardiography

               -  lungs: if respiratory problems are suspected the patient is to be excluded if the
                  resultant pulmonary function test shows FeV1<50% or a diffusion capacity <50% of
                  the reference values

               -  kidneys: creatinine >2 times the upper reference limit

               -  liver: bilirubin >2 times the upper reference limit, aspartate transaminase (AST,
                  SGOT) or alanine transaminase (ALT, SGPT) >3 x institutional upper reference
                  limit

               -  uncontrollable diabetes mellitus (prephase treatment with predniso[lo]ne!)

          3. Platelets <75 000/mm3, leukocytes <2 500/mm3 (if not due to lymphoma)

          4. Known hypersensitivity to the medications to be used

          5. Known HIV-positivity

          6. Patients with severe impairment of immune defense

          7. Patients with constipation with imminent risk of ileus

          8. Chronic active hepatitis

          9. Poor patient compliance

         10. Simultaneous participation in other treatment studies or in another clinical trial
             within the last 6 months

         11. Prior chemo- or radiotherapy, long-term use of corticosteroids or anti-neoplastic
             drugs for previous disorder

         12. Other concomitant tumour disease and/or tumour disease in the past 5 years (except for
             localised skin tumors other than melanoma and carcinomas in situ of any other origin)

         13. CNS involvement of lymphoma (intracerebral, meningeal, intraspinal intradural) or
             primary CNS lymphoma

         14. Persistent neuropathy grade ≥2 (NCI CTC-AE v4.03) (unless due to lymphoma involvement)

         15. History of persistent active neurologic disorders grade >2 including demyelinating
             form of Charcot-Marie-Tooth syndrome, acquired demyelinating disorders, or other
             demyelinating condition

         16. Pregnancy or breast-feeding women

         17. Active serious infections not controlled by oral and/or intravenous antibiotics or
             anti-fungal medication

         18. Any medical condition which in the opinion of the investigator places the subject at
             an unacceptably high risk for toxicities.

         19. MALT lymphoma

         20. Non-conformity to eligibility criteria

         21. Persons not able to understand the impact, nature, risks and consequences of the trial
             (including language barrier)

         22. Persons not agreeing to the transmission of their pseudonymous data

         23. Persons depending on sponsor or investigator

         24. Persons from highly protected groups. Pts. with CNS lymphoma should not be included in
             this study.